C07D 209/12
Radicals substituted by oxygen atoms
C07D209/12 (Radicals substituted by oxygen atoms) appears on 949 US grants and 954 published applications in this corpus.
Search patents in C07D- Granted patents
- 949
- Published applications
- 954
- Assignees
- 537
- Inventors
- 2,939
- Latest grant
- 25 Aug 2026
Filings by year
| Year | Granted patents | Published applications |
|---|---|---|
| 1976 | 9 | 0 |
| 1977 | 9 | 0 |
| 1978 | 11 | 0 |
| 1979 | 8 | 0 |
| 1980 | 8 | 0 |
| 1981 | 11 | 0 |
| 1982 | 10 | 0 |
| 1983 | 8 | 0 |
| 1984 | 7 | 0 |
| 1985 | 5 | 0 |
| 1986 | 4 | 0 |
| 1987 | 6 | 0 |
| 1988 | 3 | 0 |
| 1989 | 6 | 0 |
| 1990 | 12 | 0 |
| 1991 | 10 | 0 |
| 1992 | 15 | 0 |
| 1993 | 14 | 0 |
| 1994 | 8 | 0 |
| 1995 | 7 | 0 |
| 1996 | 9 | 0 |
| 1997 | 9 | 0 |
| 1998 | 18 | 0 |
| 1999 | 20 | 0 |
| 2000 | 15 | 0 |
| 2001 | 30 | 6 |
| 2002 | 18 | 14 |
| 2003 | 16 | 36 |
| 2004 | 20 | 39 |
| 2005 | 25 | 64 |
| 2006 | 28 | 45 |
| 2007 | 28 | 47 |
| 2008 | 28 | 49 |
| 2009 | 33 | 50 |
| 2010 | 43 | 42 |
| 2011 | 20 | 34 |
| 2012 | 32 | 23 |
| 2013 | 24 | 38 |
| 2014 | 34 | 39 |
| 2015 | 37 | 63 |
| 2016 | 38 | 44 |
| 2017 | 48 | 36 |
| 2018 | 29 | 37 |
| 2019 | 31 | 38 |
| 2020 | 26 | 30 |
| 2021 | 18 | 34 |
| 2022 | 20 | 26 |
| 2023 | 23 | 38 |
| 2024 | 26 | 39 |
| 2025 | 17 | 22 |
| 2026 | 15 | 21 |
By publication year. Applications have been published since 2001. 2026 runs to 8 Oct.
Recent patents
- Compound, preparation method therefor, composition, kit and use thereof25 Aug 2026US 12,715,844 B2Signdo Biotechnology (Suzhou) Co., Ltd
- Transcriptional enhanced associate domain (TEAD) transcription factor inhibitors and uses thereof4 Aug 2026US 12,698,259 B2Dana-Farber Cancer Institute, Inc.
- Aza-substituted psilocin analogs and methods of synthesizing the same21 Jul 2026US 12,686,660 B2Mydecine Innovations Group Inc.
- Synthesis of compounds to promote hair growth9 Jun 2026US 12,649,736 B2The Regents of the University of California
- Compositions and methods of use comprising substances with neural plasticity actions administered at non-psychedelic/psychotomimetic dosages and formulations5 May 2026US 12,616,706 B2Arbormentis LLC
- Non-Peptide Small Molecule FGF14:Nav1.6 Channel Complex Protein-Protein Interaction Modulators1 Oct 2026US 2026/0297027 A1Board of Regents, The University of Texas System
- Therapy based on synthetic lethality in swi/snf complex-dysfunction cancer27 Aug 2026US 2026/0248806 A1National Cancer Center
- Compositions and methods of use comprising substances with neural plasticity actions administered at non-psychedelic / psychotomimetic dosages and formulations13 Aug 2026US 2026/0232704 A1Arbormentis LLC
- Novel crystalline salt forms of mesembrine16 Jul 2026US 2026/0200847 A1Kanna Health LTD
- Reactive mesogens16 Jul 2026US 2026/0201251 A1Merck Patent GmbH
Most cited
By later US patents
- System and methods for nucleic acid sequencing of single molecules by polymerase synthesis410US 6,255,083 B12001
- System and method for nucleic acid sequencing by polymerase synthesis193US 7,229,799 B2LI-COR, Inc. · 2007
- Indole analogs of mevalonolactone and derivatives thereof174US 5,354,772 ASandoz Pharm. Corp. · 1994
- System and apparatus for nucleic acid sequencing of single molecules by polymerase synthesis158US 6,762,048 B2LI-COR, Inc. · 2004
- Modulators of ATP-binding cassette transporters157US 7,495,103 B2Vertex Pharmaceuticals Incorporated · 2009